Anchor Pointe Wealth Management LLC Takes $281,000 Position in Pfizer Inc. (NYSE:PFE)

Anchor Pointe Wealth Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,626 shares of the biopharmaceutical company's stock, valued at approximately $281,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter worth about $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the fourth quarter worth about $30,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

Shares of PFE stock traded up $0.26 on Thursday, reaching $23.44. The company had a trading volume of 26,085,580 shares, compared to its average volume of 41,105,682. The business's 50-day moving average is $23.22 and its 200 day moving average is $25.11. The stock has a market capitalization of $133.26 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.82 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.34%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.